Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Amod Sarnaik is prosecuting a portfolio in the Biotechnology & Pharmaceuticals technology area, which currently includes 1 pending office action. This action is being reviewed by SKOKO III, JOHN JOSEPH, the busiest examiner for the company with 1 pending action. The prosecution data shows a narrow focus with 1 distinct examiner and 1 distinct art unit. This means the 1 pending office action is the only current point of contention or review with the USPTO.
For the practitioner, the single-examiner environment in Biotechnology & Pharmaceuticals implies that the 1 distinct examiner's previous decisions and art unit trends will be the primary factors in the 1 pending action. The concentration in 1 distinct art unit indicates that the claims are highly specialized. Because the 1 pending office action represents the total active workload, the practitioner must tailor their arguments to the specific technical standards of the 1 distinct art unit involved. Success for Amod Sarnaik in this matter depends entirely on the 1 distinct examiner's interpretation of the Biotechnology & Pharmaceuticals claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17279327 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | SKOKO III, JOHN JOSEPH | 27d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17279327 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Final Rejection | 27d | Pending | Mar 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmod Sarnaik has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John Joseph Skoko III has the most, with 1 of Amod Sarnaik's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
